TISSIUM Announces Clinical Results of COAPTIUM® CONNECT System for Atraumatic Sutureless Nerve Repair
Paris, France, Cambridge, USA, April 2nd, 2025 - TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, is proud to unveil clinical data which were presented at the IFSSH Congress in Washington, D.C. on March 27, 2025, demonstrating the potential of its COAPTIUM® CONNECT System, an innovative atraumatic sutureless solution for peripheral nerve repair.
Peripheral nerve injuries pose a significant burden, often resulting in impaired nerve function, reduced dexterity, and decreased quality of life. Traditional microsurgical repair with sutures, while effective, presents challenges such as inconsistent functional recovery and the potential for additional nerve trauma. The need for disruptive technologies in nerve repair is clear—TISSIUM's COAPTIUM® CONNECT System offers an innovative atraumatic sutureless method for coaptation of severed nerves.
Study Overview & Key Findings
A prospective, single-arm study was conducted in patients with digital nerve injuries to assess the COAPTIUM® CONNECT System. The trial enrolled 12 patients, of whom 10 completed the entire 1-year follow-up duration.
100% procedural success was achieved, defined as successful atraumatic sutureless coaptation using the polymer-assisted coaptation device ;
All patients regained full flexion and extension of the injured digit ;
All patients reported no pain (VAS pain score) at 12 months ;
No study device-related complications were reported for the complete 12-month follow-up ;
No neuromas occurred.
TISSIUM would like to thank our study investigators Professor Randy Bindra, MD at the Gold Coast University Hospital and Dr. Michael Wagels at the Princess Alexandra Hospital and their study teams for their commitment to atraumatic treatment of digital nerve injuries.
The COAPTIUM® CONNECT System has been designed for atraumatic sutureless consistent nerve repair. It leverages TISSIUM's unique biopolymer platform and is comprised of a bioresorbable light-activated surgical polymer and a protective coaptation chamber.
When asked about his experience in this study, Dr. Randy Bindra, Professor of Orthopedic Surgery and principal trial investigator at the Gold Coast University Hospital and Griffith University School of Medicine said 'In my 30 years of experience of repairing nerves, this is one product where the clinical trial results have surpassed my expectation. All patients were pain free and had excellent outcomes.'
'I am optimistic this new technology can bring us a step closer to better nerve repair outcomes in the future. Removing the need for sutures will allow improved regeneration of the nerve, benefiting the patient long term,' said Dr. Michael Wagels, Director of the Australian Centre for Complex Integrated Surgical Solutions, Department of Plastic and Reconstructive Surgery, Princess Alexandra Hospital.
The COAPTIUM® CONNECT System represents a meaningful advancement in nerve surgery, offering an innovative atraumatic sutureless method for coaptation of severed nerves. By eliminating the need for microsutures, this technology streamlines nerve repair while preserving nerve integrity and function.
TISSIUM remains committed to advancing innovation in tissue reconstruction and is actively exploring the expansion of the COAPTIUM® platform for broader applications in nerve repair.
The COAPTIUM® CONNECT System is not approved or cleared by the U.S. FDA or other regulatory authorities.
***
About TISSIUM
TISSIUM, a privately-owned MedTech company based in Paris, France and Cambridge, USA, is dedicated to the development and commercialization of products derived from its unique proprietary family of fully biosynthetic, biomorphic, and programmable polymers platform. The company's products will address multiple unmet clinical needs, including atraumatic tissue repair and tissue reconstruction.
Currently, the Company has a pipeline of seven products across three verticals, including atraumatic sutureless nerve repair, atraumatic hernia repair and cardiovascular sealants. Each product is designed to enhance the tissue reconstruction process in a unique way. In addition, the company develops complementary delivery and activation devices for enhanced performance and usability of its products.
TISSIUM's technology is based on world-class research and intellectual property from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women's Hospital), who co-founded the company in 2013.
For more information, please visit: www.TISSIUM.com and follow us on LinkedIn: TISSIUM.
***
Contact
Romain Attard – Chief Financial Officer rattard@tissium.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
4 hours ago
- Miami Herald
This T-Mobile free phone offer may be its hottest deal yet
T-Mobile is one of the largest cell phone carriers in the U.S., and it's only been growing. In fact, the company reported a surge in new postpaid customers in the first quarter of 2025 and boasted impressive revenue growth. It's also been adding some exciting new technologies as well as embracing old features that customers missed. Don't miss the move: Subscribe to TheStreet's free daily newsletter For example, the company recently brought back self-service SIM changes so customers can swap out their devices more easily. This is a game-changer for those who don't want to call customer service for upgrades or after a lost device. The un-carrier has also partnered with Starlink to become the first mobile phone provider to offer both a mobile and satellite network on existing devices, so you can send texts from anywhere. The company is actually offering this service in beta testing to everyone, regardless of who their phone service provider is. However, that's not all T-Mobile has been up to. It's been making some amazing phone offers lately as it adds impressive new devices to its lineup. And, now a deal that was already pretty great has just gotten even sweeter with T-Mobile's new promotional offer. Image source: Bloomberg/Getty Images While T-Mobile's phone lineup has lagged behind competitors in terms of diversity of offerings, the company's addition of the Samsung Galaxy S25 Edge to its offerings is sure to make many customers happy, as it's a powerhouse of a phone packed into a small device. It's ultra-light and one of the slimmest phones on the market, but it has an impressive array of features beyond its size, including a Snapdragon® 8 Elite next-gen processor, a 200 MP camera, which no other Samsung device can beat, and Galaxy AI to help with everyday tasks. Related: T-Mobile shares game-changing tech, free for anyone to try Samsung's price for the phone is reflective of all that it offers, though. The price is $1,099.99 or, if financed over time through T-Mobile, $45.85 per month for two years. While this is far from the most expensive phone on the market, it's still a big chunk of change - but not if you take advantage of T-Mobile's amazing deals, including a new offer that may be the most competitive yet. T-Mobile has already offered some impressive deals on the Samsung Galaxy S25, including providing the phone totally free to anyone who had an eligible device to trade in, regardless of the device's condition. The carrier's latest deal, though, does not even require a device to trade. In fact, if you just add a line on the Experience Beyond or the Go5G Next service plans and you agree to make monthly payments, you'll pay nothing at all for one of the hottest new phones on the market. Related: Some T-Mobile customers get massive new discount The steep discount on the new phone comes in the form of 24 monthly bill credits applied to your account, which is pretty standard for cell phone deals. Of course, if you cancel your account before you earn the 24 credits, you'll owe the full balance due on your finance agreement. Still, if you have been waiting to add a line to your T-Mobile account, especially for someone new to cell phone use without a trade-in, this deal is one that you are not going to find too often. Of course, you still also have the option to score this phone free with a trade-in if preferred. More Retail: Costco quietly plans to offer a convenient service for customersT-Mobile pulls the plug on generous offer, angering customersKellogg sounds alarm on unexpected shift in customer behavior But for those who want to keep all of their existing devices or who don't have one to trade in, it's worth jumping on this amazing new offer. Free $1,000 phones with such limited qualifying requirements don't come around too often. Related: Veteran fund manager revamps stock market forecast The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Business Wire
7 hours ago
- Business Wire
New Nubz Chew Treats from Nylabone Add a Burst of Flavor to the Dog Days of Summer
NEPTUNE CITY, N.J.--(BUSINESS WIRE)--Nylabone, an iconic brand in the Central Garden & Pet portfolio (NASDAQ: CENT) (NASDAQ: CENTA), is bringing even more tail-wagging joy to treat time with the launch of Nubz® Flavor Bursts chew treats – a flavorful addition to its popular Nubz® dog treat line, just in time for summer snacking. Nubz® Flavor Bursts chew treats are now available on and ready to add a flavorful new twist to your dog's summer routine. Share Made with real cheddar cheese and irresistible bacon flavor, these natural chew treats are crafted using innovative technology that encapsulates savory flavor bursts throughout each chew, not just on the surface. They're also the newest wheat-free and corn-free addition to the Nubz® collection—perfect for providing grain-sensitive dogs the excitement they deserve in their treats. 'Summer is all about embracing fun and indulging in bold flavors, and Flavor Bursts chew treats deliver it all in one mouthwatering yet guilt-free reward,' said Glen S. Axelrod, President and CEO of Nylabone Products. 'They combine everything pet parents and dogs love about Nubz—natural, real ingredients; irresistible flavor; and USA-made quality—and leave out the corn and wheat, making them an accessible treating option for dogs with dietary needs.' Crafted with a highly digestible potato starch recipe, Nubz® Flavor Bursts contain no artificial preservatives, colors, or fillers. They also feature the brand's namesake dental textures to promote healthy teeth and gums, can easily break in half for smaller treats, and are proudly made in the USA. Nubz® Flavor Bursts chew treats are now available on and ready to add a flavorful new twist to your dog's summer routine. About Nylabone Nylabone, a leader in healthy chewing since 1955, crafts high-quality chew toys, tasty chew treats, exciting play toys, and innovative dental solutions. A family-founded company, Nylabone has a history of helping pet parents take the best possible care of their dogs. They are committed to developing world-class solutions for destructive chewing, separation anxiety, dental health, and more, helping dogs live fuller, happier lives. Recommended by veterinarians, Nylabone® products encourage a positive relationship between humans and their furry best friends. To put it simply, Nylabone Chews Best! TM For more information, visit Nylabone is a brand owned by TFH Publications, Inc. TFH Publications, Inc. is a subsidiary of California-based Central Garden & Pet Company (NASDAQ: CENT) (NASDAQ: CENTA) and has been a leader in responsible animal care for over 70 years. About Central Garden & Pet Central Garden & Pet Company (NASDAQ: CENT) (NASDAQ: CENTA) understands that home is central to life and has proudly nurtured happy and healthy homes for over 45 years. With fiscal 2024 net sales of $3.2 billion, Central is on a mission to lead the future of the pet and garden industries. The Company's innovative and trusted products are dedicated to helping lawns grow greener, gardens bloom bigger, pets live healthier, and communities grow stronger. Central is home to a leading portfolio of more than 65 high-quality brands including Amdro®, Aqueon®, Cadet®, C&S®, Farnam®, Ferry-Morse®, Four Paws®, Kaytee®, Nylabone® and Pennington®, strong manufacturing and distribution capabilities, and a passionate, entrepreneurial growth culture. Central is based in Walnut Creek, California, with over 6,000 employees, primarily across North America. Visit to learn more.
Business Wire
11 hours ago
- Business Wire
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)
COPENHAGEN, Denmark--(BUSINESS WIRE)-- Genmab A/S (Nasdaq: GMAB) today announced new results from the Phase 1b/2 EPCORE ® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in adult patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) who are eligible for autologous stem cell transplantation (ASCT). Results demonstrated an overall response rate (ORR) of 87 percent, a complete response (CR) rate of 65 percent and a partial response (PR) of 23 percent. The majority of patients (65 percent) proceeded to ASCT. At six months, an estimated 81 percent of responses were ongoing, 74 percent of patients were progression free, and 100 percent of patients were alive. These results were shared today during an oral presentation at the 30 th European Hematology Association (EHA) 2025 Congress. The safety profile of this combination therapy showed cytokine release syndrome (CRS) being low grade and no discontinuations due to treatment-emergent adverse events (TEAEs). The most common TEAEs were neutropenia (74 percent), anemia (68 percent), and thrombocytopenia (68 percent). CRS occurred in 52 percent; all were low grade (1/2) and resolved. One patient had immune effector cell-associated neurotoxicity syndrome (ICANS; grade 1), which resolved. No clinical tumor lysis syndrome was observed. Infections occurred in 18 patients (58 percent); five (16 percent) had serious infections. There were no Grade 5 TEAEs. 'These results are particularly encouraging because many of the patients in this study had high-risk disease, having progressed rapidly after initial treatment,' said Raul Cordoba, MD, PhD, Head of the Lymphoma Unit at the Fundacion Jimenez Diaz University Hospital, Madrid, Spain. 'This combination therapy of epcoritamab plus rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) offers a potential new treatment option for patients with relapsed/refractory diffuse large B-cell lymphoma, providing high response rates and a bridge to potentially curative autologous stem cell transplantation." Among patients in the study who progressed within 12 months after first-line treatment (n=20), epcoritamab in combination with R-ICE demonstrated an 85 percent ORR and 55 percent CR. Patients in the study who progressed after 12 months from first-line therapy experienced a 91 percent ORR and 82 percent CR. Additionally, patients with one prior line of therapy experienced an 88 percent ORR and 68 percent CR, and patients who were treated with more than one prior line of therapy experienced an 83 percent ORR and 50 percent CR. 'The results from this trial highlight the potential of this investigational epcoritamab containing regimen, especially in patients who progress quickly after initial treatment, and reinforce our joint efforts with AbbVie to develop epcoritamab as a core therapy for B-cell lymphomas, especially as we develop epcoritamab in earlier lines of therapy and a broader patient population,' said Dr. Judith Klimovsky, Executive Vice President and Chief Development Officer of Genmab. 'Our comprehensive EPCORE clinical trial program is dedicated to advancing epcoritamab as both monotherapy and in combination to address the significant unmet need in relapsed/refractory diffuse large B-cell lymphoma and other hematologic malignancies." Use of epcoritamab + R-ICE in patients with R/R DLBCL eligible for ASCT is not approved and the safety and efficacy of epcoritamab for use as a combination therapy in DLBCL have not been established. About Diffuse Large B-Cell Lymphoma DLBCL is the most common type of non-Hodgkin's lymphoma (NHL) worldwide, accounting for approximately 25-30 percent of all NHL cases. In the U.S., there are approximately 25,000 new cases of DLBCL diagnosed each year. DLBCL can arise in lymph nodes as well as in organs outside of the lymphatic system, occurs more commonly in the elderly and is slightly more prevalent in men. DLBCL is a fast-growing type of NHL, a cancer that develops in the lymphatic system and affects B-cell lymphocytes, a type of white blood cell. For many people living with DLBCL, their cancer either relapses, which means it may return after treatment, or becomes refractory, meaning it does not respond to treatment. Although new therapies have become available, treatment management can remain a challenge. About the EPCORE ® NHL-2 Trial EPCORE NHL-2 is a Phase 1b/2 open-label interventional trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics/biomarkers, immunogenicity, and preliminary efficacy of epcoritamab as a monotherapy and in combination with other standard of care agents in patients with B-cell non-Hodgkin's lymphoma (B-NHL). The trial consists of two parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). The primary objective of Part 1 is safety, and the primary goal of Part 2 is preliminary efficacy. The primary endpoint was overall response rate (ORR) based on best overall response per Lugano criteria. MRD negativity was assessed as a secondary endpoint. Arm 10 of the EPCORE NHL-2 study enrolled 31 patients with R/R DLBCL, who were eligible for R-ICE and ASCT, and had received ≥1 prior line of treatment. At the time of data cutoff (December 18, 2024), median follow-up was 11 months (range, 6−15). Among the 31 patients treated with epcoritamab 48 mg + R-ICE, 61 percent were Ann Arbor stage III/IV, 42 percent had bulky disease ≥7 cm, 81 percent had one prior LOT (range, 1−3), and 65 percent had progressed within 12 months of first-line treatment. More information on this trial can be found at (NCT: 04663347). About Epcoritamab Epcoritamab is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody ® technology and administered subcutaneously. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response toward target cell types. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T-cell-mediated killing of CD20+ cells. i Epcoritamab (approved under the brand name EPKINLY ® in the U.S. and Japan, and TEPKINLY ® in the EU) has received regulatory approval in certain lymphoma indications in several territories. Where approved, epcoritamab is available as a readily accessible therapy without the need for reducing tumor burden ('debulking'). Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies' oncology collaboration. The companies will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. Both companies will pursue additional international regulatory approvals for the investigational R/R FL indication and additional approvals for the R/R DLBCL indication. Genmab and AbbVie continue to evaluate the use of epcoritamab as a monotherapy, and in combination, across lines of therapy in a range of hematologic malignancies. This includes five ongoing Phase 3, open-label, randomized trials including a trial evaluating epcoritamab as a monotherapy in patients with R/R DLBCL compared to investigators choice chemotherapy (NCT04628494), a trial evaluating epcoritamab in combination with R-CHOP in adult patients with newly diagnosed DLBCL (NCT05578976), a trial evaluating epcoritamab in combination with rituximab and lenalidomide (R2) in patients with R/R FL (NCT05409066), a trial evaluating epcoritamab in combination with rituximab and lenalidomide (R2) compared to chemoimmunotherapy in patients with previously untreated FL (NCT06191744), and a trial evaluating epcoritamab in combination with R2 compared to chemotherapy infusion in patients with R/R DLBCL (NCT06508658). The safety and efficacy of epcoritamab has not been established for these investigational uses. Please visit for more information. EPKINLY ® (epcoritamab-bysp) U.S. INDICATIONS & IMPORTANT SAFETY INFORMATION What is EPKINLY? EPKINLY is a prescription medicine used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, or follicular lymphoma (FL) that has come back or that did not respond to previous treatment after receiving 2 or more treatments. EPKINLY is approved based on patient response data. Studies are ongoing to confirm the clinical benefit of EPKINLY. It is not known if EPKINLY is safe and effective in children. Important Warnings—EPKINLY can cause serious side effects, including: Cytokine release syndrome (CRS), which is common during treatment with EPKINLY and can be serious or life-threatening. To help reduce your risk of CRS, you will receive EPKINLY on a step-up dosing schedule (when you receive 2 or 3 smaller step-up doses of EPKINLY before your first full dose during your first cycle of treatment), and you may also receive other medicines before and for 3 days after receiving EPKINLY. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule. Neurologic problems that can be life-threatening and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY. People with DLBCL or high-grade B-cell lymphoma should be hospitalized for 24 hours after receiving their first full dose of EPKINLY on day 15 of cycle 1 due to the risk of CRS and neurologic problems. Tell your healthcare provider or get medical help right away if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious; headache; confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. These may be symptoms of CRS or neurologic problems. If you have any symptoms that impair consciousness, do not drive or use heavy machinery or do other dangerous activities until your symptoms go away. EPKINLY can cause other serious side effects, including: Infections that may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment and treat you as needed if you develop an infection. You should receive medicines from your healthcare provider before you start treatment to help prevent infection. Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, or feeling weak or generally unwell. Low blood cell counts, which can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including low white blood cells (neutropenia), which can increase your risk for infection; low red blood cells (anemia), which can cause tiredness and shortness of breath; and low platelets (thrombocytopenia), which can cause bruising or bleeding problems. Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects. Before you receive EPKINLY, tell your healthcare provider about all your medical conditions, including if you have an infection, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. If you receive EPKINLY while pregnant, it may harm your unborn baby. If you are a female who can become pregnant, your healthcare provider should do a pregnancy test before you start treatment with EPKINLY and you should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY. In DLBCL or high-grade B-cell lymphoma, the most common side effects of EPKINLY include CRS, tiredness, muscle and bone pain, injection site reactions, fever, stomach-area (abdominal) pain, nausea, and diarrhea. The most common severe abnormal laboratory test results include decreased white blood cells, decreased red blood cells, and decreased platelets. In follicular lymphoma the most common side effects of EPKINLY include injection site reactions, CRS, COVID-19, tiredness, upper respiratory tract infections, muscle and bone pain, rash, diarrhea, fever, cough, and headache. The most common severe abnormal laboratory test results include decreased white blood cells and decreased red blood cells. These are not all of the possible side effects of EPKINLY. Call your doctor for medical advice about side effects. You are encouraged to report side effects to the FDA at (800) FDA-1088 or or to Genmab US, Inc. at 1-855-4GENMAB (1-855-443-6622). Please see Full Prescribing Information and Medication Guide, including Important Warnings. Globally, prescribing information varies; refer to the individual country product label for complete information. About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab's vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO ®) antibody medicines. Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit and follow us on LinkedIn and X. This Media Release contains forward looking statements. The words 'believe,' 'expect,' 'anticipate,' 'intend' and 'plan' and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. Genmab A/S and/or its subsidiaries own the following trademarks: Genmab ®; the Y-shaped Genmab logo ®; Genmab in combination with the Y-shaped Genmab logo ®; HuMax ®; DuoBody ®; HexaBody ®; DuoHexaBody ®, HexElect ® and KYSO™. EPCORE ®, EPKINLY ®, TEPKINLY ® and their designs are trademarks of AbbVie Biotechnology Ltd. i Engelberts PJ, et al. DuoBody-CD3xCD20 Induces Potent T-Cell-Mediated Killing of Malignant B Cells in Preclinical Models and Provides Opportunities for Subcutaneous Dosing. EBioMedicine
